Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes (DapaDream)
A Randomized, Double-Blind, Placebo-controlled, Single-center, Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to Day and Night Closed-loop Control in Patients Type 1 Diabetes (T1D)
Sponsor: Alcedis GmbH
Listed as NCT02987738, this PHASE1 trial focuses on Type1diabetes and remains completed. Sponsored by Alcedis GmbH, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Enrolling By Invitation → Completed
-
May 2017 — Mar 2018 [monthly]
Enrolling By Invitation PHASE1
Status: Recruiting → Enrolling By Invitation
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alcedis GmbH
- AstraZeneca
- Kinderkrankenhaus auf der Bult
For direct contact, visit the study record on ClinicalTrials.gov .